leflunomide

P2, N=27, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=56 --> 27 | Trial completion date: Jul 2026 --> Jan 2027 | Trial primary completion date: Jul 2026 --> Jan 2027

P2/3, N=46, Recruiting, University of Guadalajara | Not yet recruiting --> Recruiting

P2/3, N=46, Not yet recruiting, University of Guadalajara | Trial completion date: Dec 2027 --> Jan 2027 | Trial primary completion date: Jun 2025 --> Dec 2026

P=N/A, N=110, Recruiting, Foundation University Islamabad

P2, N=53, Not yet recruiting, The Third Affiliated Hospital of Naval Medical University (Shanghai Eastern Hepatobiliary Surgery Hospital); The Third Affiliated Hospital of Naval Me

P=N/A, N=3, Terminated, University Hospital, Basel, Switzerland | N=15 --> 3 | Active, not recruiting --> Terminated; The study was prematurely terminated due to significant difficulties in recruiting participants, arising from the extremely rare nature of the targeted gene mutation.

P4, N=100, Recruiting, Tongji Hospital | Enrolling by invitation --> Recruiting | Trial completion date: Dec 2025 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Oct 2026

We demonstrate that BCOR-deficient cells have a heightened sensitivity to DHODH inhibitors such as brequinar and leflunomide, that are already in clinical use. Rather, DHODH's role in the electron transport chain, essential for mitigating reactive oxygen species, may be the physiological vulnerability that pushes BCOR-mutant cells toward cell death when DHODH is inhibited. DHODH inhibitors could be repurposed as targeted therapies for BCOR-mutant tumors, offering a promising strategy for precision medicine in AML and other cancers.

It is a pyrimidine synthesis inhibitor that has an inhibiting effect of tumor necrosis factor alpha (TNF α) signaling. We present a case of with generalized pustular skin lesions after intake of leflunomide, which resemble a pustular exacerbation of a pre-existing psoriasis as well as a generalized pustular psoriasis.

P1, N=1, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2025 --> Nov 2026 | Trial primary completion date: Dec 2025 --> Nov 2026

P2/3, N=70, Completed, Ain Shams University | Active, not recruiting --> Completed

P=N/A, N=50, Recruiting, King Chulalongkorn Memorial Hospital | Trial completion date: Jan 2026 --> Jul 2026 | Trial primary completion date: Sep 2025 --> Dec 2025